{
  "id": 20781297,
  "title": "2 Growth Stocks to Buy in November Without Any Hesitation",
  "url": "https://urgent.news/2026/11/19/2-growth-stocks-to-buy-in-november-without-any-hesitation",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T17:43:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/19/2-growth-stocks-to-buy-in-november-without-any-hesitation/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "2 biotech stocks to add to your portfolio this November are Vertex Pharmaceuticals and Regeneron. Both companies have shown strong growth this year, despite a slow start to 2026. Vertex recently received approval for a new drug called povetacicept, which is expected to be approved by the end of November. This medicine could diversify Vertex's revenue streams beyond its dominant cystic fibrosis (CF) products. Regeneron also has an attractive pipeline, including the highly successful Dupixent for eczema and a newer higher-dose formulation of its Eylea eye medicine. Both stocks appear to have strong potential for growth, making them solid options to consider adding to your portfolio in November.",
  "summary": "Vertex and Regeneron started 2026 slowly, but blockbuster results and deep pipelines have both stocks climbing again.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "2 Growth Stocks to Buy in November Without Any Hesitation",
        "url": "https://urgent.news/2026/11/19/2-growth-stocks-to-buy-in-november-without-any-hesitation-20783280",
        "published": "2026-11-19T18:03:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}